PTPN2 and neoplasm: Yang et al.1842023 first proposed a bioorthogonal response-mediated CRISPR/Cas tumor-targeted delivery system that combines the STING activation pathway and the protein tyrosine phosphatase non-receptor type 2 Gene deletion mechanism, resulting in a significant enhancement of anti-tumor immunity.